• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

粪便微生物移植治疗儿童艰难梭菌感染的疗效。

Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children.

机构信息

Vanderbilt University Medical Center, Nashville, Tennessee.

Boston Children's Hospital, Boston, Massachusetts.

出版信息

Clin Gastroenterol Hepatol. 2020 Mar;18(3):612-619.e1. doi: 10.1016/j.cgh.2019.04.037. Epub 2019 Apr 19.

DOI:10.1016/j.cgh.2019.04.037
PMID:31009795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7549313/
Abstract

BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is commonly used to treat Clostridium difficile infection (CDI). CDI is an increasing cause of diarrheal illness in pediatric patients, but the effects of FMT have not been well studied in children. We performed a multi-center retrospective cohort study of pediatric and young adult patients to evaluate the efficacy, safety, and factors associated with a successful FMT for the treatment of CDI.

METHODS

We performed a retrospective study of 372 patients, 11 months to 23 years old, who underwent FMT at 18 pediatric centers, from February 1, 2004, to February 28, 2017; 2-month outcome data were available from 335 patients. Successful FMT was defined as no recurrence of CDI in the 2 months following FMT. We performed stepwise logistic regression to identify factors associated with successful FMT.

RESULTS

Of 335 patients who underwent FMT and were followed for 2 months or more, 271 (81%) had a successful outcome following a single FMT and 86.6% had a successful outcome following a first or repeated FMT. Patients who received FMT with fresh donor stool (odds ratio [OR], 2.66; 95% CI, 1.39-5.08), underwent FMT via colonoscopy (OR, 2.41; 95% CI, 1.26-4.61), did not have a feeding tube (OR, 2.08; 95% CI, 1.05-4.11), or had 1 less episode of CDI before FMT (OR, 1.20; 95% CI, 1.04-1.39) had increased odds for successful FMT. Seventeen patients (4.7%) had a severe adverse event during the 3-month follow-up period, including 10 hospitalizations.

CONCLUSIONS

Based on the findings from a large multi-center retrospective cohort, FMT is effective and safe for the treatment of CDI in children and young adults. Further studies are required to optimize the timing and method of FMT for pediatric patients-factors associated with success differ from those of adult patients.

摘要

背景与目的

粪便微生物群移植(FMT)常用于治疗艰难梭菌感染(CDI)。CDI 是儿童腹泻病日益增多的病因,但 FMT 对儿童的疗效尚未得到很好的研究。我们进行了一项多中心回顾性队列研究,以评估粪便微生物群移植治疗 CDI 的疗效、安全性和与成功治疗相关的因素。

方法

我们对 2004 年 2 月 1 日至 2017 年 2 月 28 日在 18 家儿科中心接受 FMT 的 372 名 11 个月至 23 岁的儿科和年轻成人患者进行了回顾性研究;335 名患者可获得 2 个月的随访结果。成功的 FMT 定义为 FMT 后 2 个月内 CDI 无复发。我们进行逐步逻辑回归以确定与成功 FMT 相关的因素。

结果

在 335 名接受 FMT 并随访 2 个月或更长时间的患者中,271 名(81%)在单次 FMT 后获得成功结局,86.6%在首次或重复 FMT 后获得成功结局。接受新鲜供体粪便 FMT(比值比 [OR],2.66;95%置信区间 [CI],1.39-5.08)、接受结肠镜 FMT(OR,2.41;95%CI,1.26-4.61)、无喂养管(OR,2.08;95%CI,1.05-4.11)或在 FMT 前 CDI 发作次数少 1 次(OR,1.20;95%CI,1.04-1.39)的患者,其 FMT 成功的可能性更高。在 3 个月的随访期间,17 名患者(4.7%)发生 17 例严重不良事件,包括 10 例住院。

结论

基于一项大型多中心回顾性队列研究的结果,FMT 对儿童和年轻成人 CDI 的治疗是有效且安全的。需要进一步研究来优化儿科患者的 FMT 时机和方法-与成人患者相关的成功因素不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fac/7549313/66e3578db338/nihms-1633139-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fac/7549313/66e3578db338/nihms-1633139-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fac/7549313/66e3578db338/nihms-1633139-f0001.jpg

相似文献

1
Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children.粪便微生物移植治疗儿童艰难梭菌感染的疗效。
Clin Gastroenterol Hepatol. 2020 Mar;18(3):612-619.e1. doi: 10.1016/j.cgh.2019.04.037. Epub 2019 Apr 19.
2
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).粪便微生物移植治疗复发性艰难梭菌(艰难梭菌)。
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
3
Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.微生物定植与粪菌移植治疗炎症性肠病和非炎症性肠病患者艰难梭菌感染的疗效。
Inflamm Bowel Dis. 2019 May 4;25(6):969-979. doi: 10.1093/ibd/izy398.
4
Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.粪便微生物群移植对多次复发性艰难梭菌感染复发的影响:一项随机试验
Ann Intern Med. 2016 Nov 1;165(9):609-616. doi: 10.7326/M16-0271. Epub 2016 Aug 23.
5
Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis.粪便微生物移植在艰难梭菌感染和肝硬化患者中是安全有效的。
Clin Gastroenterol Hepatol. 2021 Aug;19(8):1627-1634. doi: 10.1016/j.cgh.2020.06.051. Epub 2020 Jul 6.
6
Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Infection.与感染患者粪便微生物群移植结局相关的因素。
Gut Liver. 2021 Jan 15;15(1):61-69. doi: 10.5009/gnl20135.
7
Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.粪便微生物群移植治疗复发性肠道艰难梭菌感染 - 十年单中心经验。
Cas Lek Cesk. 2022 Summer;161(3-4):126-130.
8
Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort.免疫功能低下人群中粪菌移植治疗艰难梭菌感染安全有效。
Dig Dis Sci. 2022 Oct;67(10):4866-4873. doi: 10.1007/s10620-021-07347-x. Epub 2022 Jan 9.
9
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.造血干细胞移植受者复发性艰难梭菌感染的粪便微生物群移植
Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5.
10
Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.炎症性肠病影响复发性艰难梭菌感染粪便微生物群移植的结果。
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1433-8. doi: 10.1016/j.cgh.2016.02.018. Epub 2016 Feb 22.

引用本文的文献

1
The early-life gut microbiome in common pediatric diseases: roles and therapeutic implications.常见儿科疾病中的早期肠道微生物群:作用及治疗意义
Front Nutr. 2025 May 29;12:1597206. doi: 10.3389/fnut.2025.1597206. eCollection 2025.
2
Fecal microbiota transplantation-current perspective on human health.粪便微生物群移植——对人类健康的当前观点
Front Med (Lausanne). 2025 Mar 14;12:1523870. doi: 10.3389/fmed.2025.1523870. eCollection 2025.
3
Fecal Microbiota Transplantation for Refractory Infection Post Haploidentical Transplant for Pediatric Acute Myeloid Leukemia.

本文引用的文献

1
Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.粪便微生物移植治疗儿童复发性艰难梭菌感染和其他疾病:北美儿童胃肠病学、肝病学和营养学学会与欧洲儿童胃肠病学、肝病学和营养学学会联合立场文件。
J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):130-143. doi: 10.1097/MPG.0000000000002205.
2
Association Between Use of Acid-Suppressive Medications and Antibiotics During Infancy and Allergic Diseases in Early Childhood.婴幼儿时期使用抑酸药物和抗生素与儿童早期过敏疾病的关系。
JAMA Pediatr. 2018 Jun 4;172(6):e180315. doi: 10.1001/jamapediatrics.2018.0315.
3
单倍体相合移植治疗儿童急性髓系白血病后难治性感染的粪便微生物群移植
Blood Cell Ther. 2025 Feb 14;8(1):170-172. doi: 10.31547/bct-2024-015. eCollection 2025 Feb 25.
4
Post-transplant diarrhea in pediatric kidney transplant recipients.小儿肾移植受者的移植后腹泻
Pediatr Nephrol. 2025 Feb 5. doi: 10.1007/s00467-024-06572-6.
5
Protective effect of gut microbiota restored by fecal microbiota transplantation in a sepsis model in juvenile mice.粪菌移植重建肠道菌群对幼年脓毒症模型小鼠的保护作用。
Front Immunol. 2024 Oct 22;15:1451356. doi: 10.3389/fimmu.2024.1451356. eCollection 2024.
6
A gut check: understanding the interplay of the gastrointestinal microbiome and the developing immune system towards the goal of pediatric HIV remission.肠道检查:了解胃肠道微生物组与发育中免疫系统的相互作用,以期实现儿科 HIV 缓解。
Retrovirology. 2024 Oct 18;21(1):15. doi: 10.1186/s12977-024-00648-9.
7
[Advances in the treatment of infection in children].[儿童感染性疾病的治疗进展]
Zhongguo Dang Dai Er Ke Za Zhi. 2024;26(9):995-1001. doi: 10.7499/j.issn.1008-8830.2405055.
8
Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after fecal microbiota transplant in inflammatory bowel disease.较高的 alpha 多样性和乳杆菌丰度与炎症性肠病粪菌移植后的更好植入相关。
Sci Rep. 2024 Aug 6;14(1):18188. doi: 10.1038/s41598-024-68619-w.
9
Clostridioides difficile Infections: Prevention and Treatment Strategies.艰难梭菌感染:预防与治疗策略。
Adv Exp Med Biol. 2024;1449:175-186. doi: 10.1007/978-3-031-58572-2_11.
10
Fecal microbiota transplantation: current challenges and future landscapes.粪便微生物群移植:当前的挑战和未来的前景。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0006022. doi: 10.1128/cmr.00060-22. Epub 2024 May 8.
National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014.2003年至2014年退伍军人健康管理局中初次和复发性艰难梭菌感染的全国流行病学情况。
PLoS One. 2017 Dec 7;12(12):e0189227. doi: 10.1371/journal.pone.0189227. eCollection 2017.
4
An Intragastric Fecal Microbiota Transplantation Program for Treatment of Recurrent Clostridium difficile in Children is Efficacious, Safe, and Inexpensive.一项用于治疗儿童复发性艰难梭菌感染的胃内粪菌移植方案具有疗效好、安全性高且费用低廉的特点。
J Pediatr. 2018 Mar;194:123-127.e1. doi: 10.1016/j.jpeds.2017.10.016. Epub 2017 Dec 1.
5
Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients.粪便微生物群移植治疗儿科造血干细胞移植受者复发性艰难梭菌感染
J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):e6-e8. doi: 10.1093/jpids/pix076.
6
The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis.粪便微生物群移植后炎症性肠病发作的风险:系统评价和荟萃分析。
Gut Microbes. 2017 Nov 2;8(6):574-588. doi: 10.1080/19490976.2017.1353848. Epub 2017 Sep 12.
7
Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection.系统评价与荟萃分析:粪便微生物群移植治疗复发性和难治性艰难梭菌感染的疗效
Aliment Pharmacol Ther. 2017 Sep;46(5):479-493. doi: 10.1111/apt.14201. Epub 2017 Jul 14.
8
Current challenges in the treatment of severe infection: early treatment potential of fecal microbiota transplantation.重症感染治疗中的当前挑战:粪便微生物群移植的早期治疗潜力
Therap Adv Gastroenterol. 2017 Apr;10(4):373-381. doi: 10.1177/1756283X17690480. Epub 2017 Feb 8.
9
Changes in Composition of the Gut Bacterial Microbiome after Fecal Microbiota Transplantation for Recurrent Infection in a Pediatric Heart Transplant Patient.一名小儿心脏移植患者因反复感染接受粪便微生物群移植后肠道细菌微生物群组成的变化
Front Cardiovasc Med. 2017 Apr 4;4:17. doi: 10.3389/fcvm.2017.00017. eCollection 2017.
10
Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice.肠易激综合征患者的粪便微生物群移植可改变受体小鼠的肠道功能和行为。
Sci Transl Med. 2017 Mar 1;9(379). doi: 10.1126/scitranslmed.aaf6397.